Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vor Biopharma ( (VOR) ) has issued an update.
Vor Biopharma recently experienced significant changes in its Board of Directors with the resignation of three members: Joshua Resnick, Matthew Patterson, and David Lubner in late August 2025. These resignations were not due to any disagreements with the company. Subsequently, Sarah Reed was appointed to the Board on August 27, 2025, filling one of the vacancies. Reed, who brings extensive legal and academic experience, was nominated by RA Capital, a significant shareholder in Vor Biopharma. Her appointment aligns with the company’s ongoing relationship with RA Capital, which holds a substantial voting stake in the company.
The most recent analyst rating on (VOR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Average Trading Volume: 17,597,564
Technical Sentiment Signal: Buy
Current Market Cap: $263.5M
For a thorough assessment of VOR stock, go to TipRanks’ Stock Analysis page.